<DOC>
	<DOCNO>NCT00089739</DOCNO>
	<brief_summary>This study try identify marker immune activity uveitis patient correlate state disease activity . Uveitis group inflammatory eye disease cause vision loss . The study examine whether certain substance blood predict reactivation disease occur , therapy may influence activity substance . Previous study find possible marker call GITR ( glucocorticoid induce TNF related family receptor ) , SOCS ( suppressor cytokine secretion ) , interleukin-15 . Markers may help guide physician safely taper medicine uveitis patient . Patients 18 year age old sight-threatening uveitis may eligible study . Participants slowly taper medicine disease stable evidence significant inflammation . If disease remain inactive tapering , drug therapy eventually stop . Patients eye examination every 1 3 month disease quiet every 2 4 week flare-ups . Blood sample draw 2 3 time year . In addition , patient may follow procedure need : - Eye photography : Eye drop give enlarge pupil thorough eye examination , special camera use take photograph . - Fluorescein angiography : This test check abnormality eye blood vessel . A yellow dye inject arm vein travel blood vessel eye . Pictures retina take special camera flash blue light eye . The picture show dye leak vessel retina , indicate possible abnormality .</brief_summary>
	<brief_title>Immune Indicators Uveitis</brief_title>
	<detailed_description>Indicators disease activity suppose autoimmune condition actively seek . We already describe increased expression GITR-glucocorticoid induce TNF-related family receptor active disease decrease expression disease activity diminishes . We preliminary observation uveitis patient suggest suppressor cytokine activity ( SOCS ) 1 , 3 , 5 may also active either Th1 Th2 mediate disease . We wish see correlation marker whether serve indicator impend activation disease actual clinical disease , therapy may alter expression . Patients uveitis receive standard evaluation treatment inflammatory uveitis protocol Blood drawn specific clinical criterion reach correlation potential marker disease activity .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients bilateral sight threaten uveitis require systemic immunotherapy 18 year older eligible . Disease active quiescent , subject must minimum prescribed therapy upon enrollment dose average least 20 mg/day ( great equal 0.25 mg/kg/day ) systemic prednisone intensive immunosuppression regimen . More intensive regimen may include one three antiinflammatory treatment uveitis include one follow ( relate ) compound : corticosteroid ( include systemic periorbital administration ) , topical corticosteroid ( use combination agent ) , cyclophosphamide , cyclosporine , azathioprine , chlorambucil , tacrolimus , leflunomide , mycophenolate mofetil , methotrexate . Patients noninfectious intermediate , posterior , panuveitis least 3 month duration . Included condition may include limited intermediate uveitis par planitis subtype , sarcoidosis , VogtKoyanagiHarada ( VKH ) syndrome , birdshot retinochoroidopathy , retinal vasculitis sympathetic ophthalmia . Patients 18 year age old . EXCLUSION CRITERIA : Subjects able enroll : Are unwilling unable give blood designate time protocol . Have another disease condition affect vision interfere obtain study data Are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 28, 2008</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Suppressor Cytokine Secretion</keyword>
	<keyword>GITR</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>GITR Ligand</keyword>
	<keyword>Intraocular Inflammation</keyword>
</DOC>